Global Cancer Pain Therapeutics Market 2015-2019
About Cancer Pain Therapeutics
Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.
Technavio’s analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.
The market is divided into the following segments based on region:
Technavio Announces the Publication of its Research Report – Global Cancer Pain Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cancer Pain Therapeutics Market: BioDelivery Sciences, ProStrakan Group and Teva Pharmaceuticals
Other Prominent Vendors in the market are: Daiichi Sankyo, Eli-lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, and WEX Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “At present, the cancer pain therapeutics market has Teva Pharmaceuticals, BioDelivery Sciences, and ProStrakan Group as the key players. Teva Pharmaceutical's Actiq and Fentora; and ProStrakan's Abstral and Lazanda compete directly with BioDelivery Sciences' Onsolis. To overcome the severe competition being posed, the key players and other vendors have started differentiating their drugs in an attempt to increase profits and avoid price competition.”
According to the report, the major driving factor for the global cancer pain therapeutics market is the high unmet need for appropriate drugs in the market.
Further, the report states that the use of off-label drugs is another important challenge for the market.
BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals, Daiichi Sankyo, Eli-lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, WEX Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook